Safety of Alemtuzumab After Exposure to Chemotherapeutic Agents in Patients with Multiple Sclerosis - Experience of a single MS center (P5.367)
Single Center
Natalizumab
Center (category theory)
DOI:
10.1212/wnl.90.15_supplement.p5.367
Publication Date:
2023-12-07T11:46:32Z
AUTHORS (6)
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....